{"id":20134,"date":"2011-09-24T06:52:46","date_gmt":"2011-09-24T10:52:46","guid":{"rendered":"http:\/\/asweetlife.org\/?p=20134"},"modified":"2015-12-30T04:42:30","modified_gmt":"2015-12-30T09:42:30","slug":"eu-adopts-positive-opinion-on-levemir-as-an-add-on-therapy-to-victoza-in-type-2-diabetes-patients","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=20134","title":{"rendered":"Eu Adopts Positive Opinion on Levemir as an Add-On Therapy to Victoza in Type 2 Diabetes Patients"},"content":{"rendered":"
\n
\"\"<\/a>Following a review of new data from a\u00a0\u00a052-week clinical trial, the\u00a0European Committee for Medicinal Products for Human Use (CHMP)\u00a0adopted a positive opinion on the usage of Novo Nordisk\u2019s basal insulin analogue, Levemir, as add-on therapy to Novo Nordisk\u2019s GLP-1 analogue, Victoza, in combination with metformin in patients with type 2 diabetes.<\/div>\n
\u00a0<\/div>\n
The CHMP also adopted a positive opinion for Victoza. Although the CHMP did not consider the results of the study sufficient to support a new indication for Victoza, the Committee concluded that the new data were of importance to healthcare professionals involved in treating type 2 diabetes and recommended that they be included in the product information for Victoza.\u00a0<\/div>\n
\u00a0<\/div>\n<\/div>\n
The 52-week, randomized, open-label clinical trial was conducted to evaluate the safety and efficacy of adding once-daily Levemir to treatment with Victoza 1.8 mg plus metformin.\u00a0<\/div>\n
\u00a0<\/div>\n
\n
\n
Key findings from the study include:<\/div>\n<\/div>\n
\n
\n
    \n
  • After completing 12 weeks of treatment with Victoza and metformin, 61% of patients reached the ADA target for blood sugar control (HbA1C <7%) with mean decreases in HbA1C of 1.3% and body weight of 4.4 kg (9.7 lbs)<\/li>\n
  • After the additional 26 weeks, patients randomized to add on Levemir to Victoza and metformin had further HbA1C reductions of 0.5%, while HbA1C remained stable in the Victoza and metformin group<\/li>\n
  • Furthermore, 43% of patients in the Victoza, metformin and Levemir group reached the ADA target for blood sugar control (HbA1C <7%) at 26 weeks vs an additional 17% in the Victoza and metformin group<\/li>\n
  • Weight loss was sustained after Levemir was added.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n
    \n
    Novo Nordisk anticipates that the European Commission, within the coming months, will approve the usage of Levemir as an add-on therapy to Victoza in patients with type 2 diabetes.\u00a0<\/div>\n
    \u00a0<\/div>\n
    \u00a0<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Following a review of new data from a 52-week clinical trial, the European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the usage of Novo Nordisk\u2019s basal insulin analogue, Levemir, as add-on therapy to Novo Nordisk\u2019s GLP-1 analogue, Victoza, in combination with metformin in patients with type 2 diabetes…<\/p>\n","protected":false},"author":131,"featured_media":29375,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1443,1441],"tags":[1128,144,315],"yoast_head":"\nEu Adopts Positive Opinion on Levemir as an Add-On Therapy to Victoza in Type 2 Diabetes Patients<\/title>\n<meta name=\"description\" content=\"The CHMP adopted a positive opinion on the usage of Novo Nordisk\u2019s basal insulin analogue, Levemir, as add-on therapy to Victoza, in combination with metformin in type 2 diabetes patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=20134\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=20134\",\"url\":\"https:\/\/asweetlife.org\/?p=20134\",\"name\":\"Eu Adopts Positive Opinion on Levemir as an Add-On Therapy to Victoza in Type 2 Diabetes Patients\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=20134#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=20134#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/09\/Novo-Nordisk-Logo1.png\",\"datePublished\":\"2011-09-24T10:52:46+00:00\",\"dateModified\":\"2015-12-30T09:42:30+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"The CHMP adopted a positive opinion on the usage of Novo Nordisk\u2019s basal insulin analogue, Levemir, as add-on therapy to Victoza, in combination with metformin in type 2 diabetes patients.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=20134#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=20134\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=20134#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/09\/Novo-Nordisk-Logo1.png\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/09\/Novo-Nordisk-Logo1.png\",\"width\":215,\"height\":160,\"caption\":\"Novo Nordisk Logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=20134#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eu Adopts Positive Opinion on Levemir as an Add-On Therapy to Victoza in Type 2 Diabetes Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eu Adopts Positive Opinion on Levemir as an Add-On Therapy to Victoza in Type 2 Diabetes Patients","description":"The CHMP adopted a positive opinion on the usage of Novo Nordisk\u2019s basal insulin analogue, Levemir, as add-on therapy to Victoza, in combination with metformin in type 2 diabetes patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=20134","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=20134","url":"https:\/\/asweetlife.org\/?p=20134","name":"Eu Adopts Positive Opinion on Levemir as an Add-On Therapy to Victoza in Type 2 Diabetes Patients","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=20134#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=20134#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/09\/Novo-Nordisk-Logo1.png","datePublished":"2011-09-24T10:52:46+00:00","dateModified":"2015-12-30T09:42:30+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"The CHMP adopted a positive opinion on the usage of Novo Nordisk\u2019s basal insulin analogue, Levemir, as add-on therapy to Victoza, in combination with metformin in type 2 diabetes patients.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=20134#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=20134"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=20134#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/09\/Novo-Nordisk-Logo1.png","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/09\/Novo-Nordisk-Logo1.png","width":215,"height":160,"caption":"Novo Nordisk Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=20134#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Eu Adopts Positive Opinion on Levemir as an Add-On Therapy to Victoza in Type 2 Diabetes Patients"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/20134"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20134"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/20134\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/29375"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20134"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20134"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}